MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage […]